Ethical Considerations of Treating Patients Infected with Hepatitis C Virus

Alireza Ebrahimi; Sedigheh Ebrahimi

doi:10.5812/hepatmon.108341

Ethical Considerations of Treating Patients Infected with Hepatitis C Virus

authors:

Alireza Ebrahimi ¹ , Sedigheh Ebrahimi ^{2
, *}

1 Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Medical Ethics, Shiraz University of Medical Sciences, Shiraz, Iran

Hepatitis Monthly: Vol.20, issue 10; e108341

published online: October 30, 2020

article type: Letter

received: August 9, 2020

accepted: October 17, 2020

DOI: https://doi.org/10.5812/hepatmon.108341

how to cite: Ebrahimi A, Ebrahimi S. Ethical Considerations of Treating Patients Infected with Hepatitis C Virus. Hepat Mon. 2020;20(10):e108341. https://doi.org/10.5812/hepatmon.108341.

Keywords

Hepatitis C Ethic Barriers Treatment

Footnotes

Authors' Contribution: Study concept and design: SE. Drafting of the manuscript: AE. Critical revision of the manuscript for important intellectual content: SE. Study supervision: SE.
Conflict of Interests: The authors declare no conflict of interest regarding the publication of this paper.
Funding/Support: None declared by the author.

References

1.
Kasraian L, Hosseini S, Salehi Marzijarani M, Ebrahimi A, Ashkani-Esfahani S. The prevalence of hepatitis C infection in blood donors: A meta-analysis and systematic review. Iran Red Crescent Med J. 2020;22(1). https://doi.org/10.5812/ircmj.94998.
2.
Roche B, Coilly A, Duclos-Vallee JC, Samuel D. The impact of treatment of hepatitis C with DAAs on the occurrence of HCC. Liver Int. 2018;38 Suppl 1:139-45. [PubMed ID: 29427487]. https://doi.org/10.1111/liv.13659.
3.
Mendizabal M, Alonso C, Silva MO. Overcoming barriers to hepatitis C elimination. Frontline Gastroenterol. 2019;10(3):207-9. [PubMed ID: 31288259]. [PubMed Central ID: PMC6583574]. https://doi.org/10.1136/flgastro-2018-101114.
4.
Geppert CM, Arora S. Ethical issues in the treatment of hepatitis C. Clin Gastroenterol Hepatol. 2005;3(10):937-44. [PubMed ID: 16234037]. https://doi.org/10.1016/s1542-3565(05)00183-7.
5.
Behzadifar M, Azari S, Gorji HA, Martini M, Bragazzi NL. The hepatitis C virus in Iran: health policy, historical, ethical issues and future challenges. J Prev Med Hyg. 2020;61(1):E109-18. [PubMed ID: 32490276]. [PubMed Central ID: PMC7225642]. https://doi.org/10.15167/2421-4248/jpmh2020.61.1.1438.
6.
Danta M, Ghinea N. The complex legal and ethical issues related to generic medications. Viral hepatitis: a case study. J Virus Erad. 2017;3(2):77-81. [PubMed ID: 28435690]. [PubMed Central ID: PMC5384269].
7.
Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med. 2002;136(4):288-92. [PubMed ID: 11848726]. https://doi.org/10.7326/0003-4819-136-4-200202190-00008.
8.
Craxi L, Sacchini D, Refolo P, Minacori R, Daloiso V, Ricci G, et al. Prioritization of high-cost new drugs for HCV: making sustainability ethical. Eur Rev Med Pharmacol Sci. 2016;20(6):1044-51. [PubMed ID: 27049255].

comments